ArticleBreast cancer research : BCR2025
Dynamic tumor-infiltrating lymphocytes predicts survival in HR+/HER2- early breast cancer: a pre-to-post neoadjuvant chemotherapy study.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionThe prognostic implications of tumor-infiltrating lymphocytes (TILs) and their temporal changes (ΔTILs) during neoadjuvant chemotherapy (NAC) in hormone receptor-positive/ HER2-negative early breast cancer (HR+/HER2- eBC) remains clinically ambiguous. Our study investigates the association between TILs levels, longitudinal TILs evolution, and survival outcomes in a NAC-treated HR+/HER2- eBC cohort.
methodsIn this retrospective cohort analysis of 576 HR+/HER2- eBC patients (April 2011-December 2021), TILs were categorized as low (< 10%) or high (≥ 10%) using predefined thresholds. Multivariable Cox proportional hazards models evaluated invasive disease-free survival (iDFS) and overall survival (OS). ΔTILs patterns were analyzed in residual tumors.
resultsThe cohort (median follow-up 68.1 months) comprised 393 TILs-low (68.2%) and 183 TILs-high (31.8%) tumors. Compared to TILs-low tumors, TILs-high tumors were associated with a higher Ki-67 index (≥ 20%) (P = 0.022), even though they were more frequently of smaller baseline size (< 3 cm) (P = 0.022). Elevated pre-NAC TILs independently predicted inferior iDFS (HR = 1.47, 95% CI 1.06-2.04, P = 0.021) and OS (HR = 1.64, 95% CI 1.11-2.43, P = 0.013). Post-NAC TILs escalation (low to high) conferred the worse prognosis versus sustained low TILs (iDFS: HR = 2.97, 95% CI 1.93-4.55, P < 0.001; OS: HR = 3.43, 95% CI 2.02-5.85, P < 0.001). Conversely, TILs reduction (high to low) correlated with improved survival over persistent high TILs (iDFS: HR = 0.51, 95% CI 0.30-0.86, P = 0.012; OS: HR = 0.54, 95%CI 0.31-0.96, P = 0.034).
conclusionIn HR+/HER2- eBC, elevated pre-treatment TILs are independently associated with inferior survival outcomes, while chemotherapy-induced TILs reduction in residual disease correlates with significant prognostic improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.